Skip to content

Vibration Response Imaging in Chronic Obstructive Pulmonary Disease and Asthma

Evaluation of Vibration Response Imaging (VRI) in Chronic Obstructive Pulmonary Disease and Asthma Patients Before and After Bronchodilators

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00542282
Enrollment
75
Registered
2007-10-11
Start date
2006-11-30
Completion date
2007-08-31
Last updated
2009-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Chronic Obstructive Pulmonary Disease

Keywords

lung sounds,, airway obstruction,, asthma,, auscultation

Brief summary

Obstructive lung disease is usually a differential diagnostic consideration when a patient presents with breathlessness or cough. Spirometry is the key diagnostic test used to confirm airflow obstruction particularly in the primary care setting. Airflow obstruction that completely resolves after administration of a bronchodilator, by definition, excludes a diagnosis of COPD. Evaluation of obstructive lung disease must include pulmonary function testing; bronchoreversibility testing is an adjunct in differentiating between asthma and COPD. Bronchoreversibility cannot serve as an absolute diagnostic criterion for separating asthma from COPD. Vibration response imaging (VRI) technology provides a simple, radiation-free method to image the lungs, by visualizing vibration energy (lung sounds) emitted during respiration cycle. In this study, regional quantitative and qualitative information on vibration response is compared with spirometry in assessing lungs function of COPD and Asthma patients.

Interventions

None listed

Sponsors

Deep Breeze
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Able and willing to read, understand, and provide written Informed Consent * Male or Female in the age range of 18-85 years * Patients referred for evaluation of known or suspected obstructive airways disease. * Subject is referred for pulmonary function testing with pre-and post- bronchodilator * BMI \> 21 * Patients who are treated with Bronchodilators should go through a washout period prior the VRI procedure according to the Pulmonary Function Laboratory protocol. * Stable clinical condition at study baseline evaluation.

Exclusion criteria

* Chest wall deformation * Spine deformation (including severe scoliosis) * Hirsutism * Potentially contagious skin lesion on the back * Skin lesion that would interfere with sensor placement * Pregnant or lactating females.

Design outcomes

Primary

MeasureTime frame
The primary study objective is evaluation of the VRI qualitative and quantitative assessment before and after spirometry with bronchodilators.One day

Secondary

MeasureTime frame
The secondary objective is correlating the VRI evaluations with lung function test resultsOne day

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026